XML 38 R22.htm IDEA: XBRL DOCUMENT
v3.22.4

Earnings per Share | 12 Months Ended
--- | ---
Dec. 31, 2022
Earnings Per Share [Abstract] |
Earnings per Share | Earnings per ShareFor 2022, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for 2022, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):
| Years Ended December 31,
| 2022 |  | 2021 |
Numerator |  |  |  |
Consolidated net income | $ | 230,064 |  |  | $ | 1,241,201 |  |
Less: Net income attributable to Continuing Investors Partnerships | 23,775 |  |  | 297,321 |  |
Less: Net income attributable to Legacy Investors Partnerships and RPSFT | 163,457 |  |  | 324,152 |  |
Net income attributable to Royalty Pharma plc - basic and diluted | $ | 42,832 |  |  | $ | 619,728 |  |
Denominator |  |  |  |
Weighted average Class A ordinary shares outstanding - basic | 437,963 |  |  | 414,794 |  |
Add: Dilutive effect of unvested RSUs | 9 |  |  | 8 |  |
Weighted average Class A ordinary shares outstanding - diluted | 437,972 |  |  | 414,802 |  |
Earnings per Class A ordinary share - basic | $ | 0.10 |  |  | $ | 1.49 |  |
Earnings per Class A ordinary share - diluted | $ | 0.10 |  |  | $ | 1.49 |  |
Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares.
|  | Year Ended December 31,
|  | 2020
Numerator |  |
Consolidated net income |  | $ | 1,701,954 |
Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1) |  | 479,842 |
Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO |  | 316,993 |
Less: Net income attributable to Legacy Investors Partnerships and RPSFT |  | 409,921 |
Net income attributable to Royalty Pharma plc - basic and diluted |  | $ | 495,198 |
Denominator |  |
Weighted average Class A ordinary shares outstanding - basic |  | 375,444 |
Add: Dilutive effect of unvested RSUs |  | 11 |
Weighted average Class A ordinary shares outstanding - diluted |  | 375,455 |
Earnings per Class A ordinary share - basic |  | $ | 1.32 |
Earnings per Class A ordinary share - diluted |  | $ | 1.32 |
(1)Reflected as Net income attributable to Royalty Pharma plc on the consolidated statements of operations.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration